Immunotherapy with tumor cell subpopulations

Summary L1210 tumor subpopulations were isolated by lectin-nylon chromatography and evaluated in active, specific immunotherapy of residual L1210 leukemia (following reduction in tumor burden by chemotherapy). Immunotherapy with cells either not binding mannosylspecific columns or eluted from fucose-specific columns resulted in a higher percent of long-term survivors compared to mice treated with chemotherapy only. In contrast, immunotherapy with cells eluted from galactose-specific columns was deleterious, and abrogated the beneficial effects of chemotherapy. The results emphasize that (a) clinical immunotherapy may be either beneficial or deleterious, depending upon the properties of the tumor cell vaccine, and (b) the therapeutic value of L1210 subpopulations is related to the expression of cell-surface carbohydrates.Supported, in part, by a research contract from the National Cancer Institute, USA